PT-141 Dosage Calculator & Research Doses

1Set Up Your Mix

5 mg/mL · 5000 mcg/mL

1. Pick your peptide

2. How much peptide is in the vial? It's printed on the label — usually something like 5 mg

3. How much water are you adding? More water makes each dose easier to measure

4. How much do you want per dose?

Your Answer — PT-141

10 mg in 2 mL

20Draw To This Line

0.2That's This Many mL

10Doses In The Vial

10 mg ÷ 2 mL = 5 mg/mL → 1 mg ÷ 5 mg/mL = 0.2 mL → × 100 = 20 units

Looks good. Draw to 20 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 10 doses.

When to dose

Time of dayNo particular time of day has been established.

FoodNo fasting requirement has been established.

The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.

2Week-By-Week Plan — PT-141

Start low, work up

When	Dose	How Often	How Many mL	Draw To	Number Of Doses	Peptide Used
Weeks 1–2	1 mg	daily	0.2 mL	20 u	14	14 mg
Weeks 3–4	1.75 mg	daily	0.35 mL	35 u	14	24.5 mg
Week 5 onward per 4 weeks from here on	2 mg	daily	0.4 mL	40 u	28	56 mg

Time until the top dose

4 weeks

Peptide used getting there

38.5 mg

Vials you'll need

4 × 10 mg

Once you're at the top dose

56 mg / 4 wk · 5.6 vials

Where this plan came from

Built from this peptide's dose range

Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — PT-141

worked out for your mix

Level	Dose	How Often	How Many mL	Draw To	Doses In Vial
Label dose	1.75 mg	as needed, max 1×/24 h	0.35 mL	35 u	5 doses
Lower reported	1 mg	as needed	0.2 mL	20 u	10 doses
Trial upper	2 mg	as needed	0.4 mL	40 u	5 doses

Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About PT-141

Endocrine & Sexual Health

Also known as

Bremelanotide, Vyleesi

Class

Endocrine & Sexual Health

Route

Subcutaneous

Half-life

~2.7 h

Evidence tier

Clinical

An FDA-approved melanocortin-4 agonist for hypoactive sexual desire disorder in premenopausal women. The 1.75 mg label dose is well defined; nausea is the dominant adverse effect and transient blood pressure elevation is documented.

Buy PT-141

Research Equipment

SyringesU-100 insulin · 1 mL · 29–31G

Alcohol wipes70% isopropyl prep pads

Serum base — for topical mixesHyaluronic acid serum for mixing peptides into a serum

Electric cooler caseTSA-approved travel cooler — keeps mixed vials at fridge temperature

Storage caseHard carry case for vials

Paid affiliate links.

Common Questions — PT-141

How much bacteriostatic water do I add to a 10 mg vial of PT-141?

Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of PT-141 is used in research?

Published and reported figures for PT-141 run from 1 mg to 2 mg, typically as needed. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 1.75 mg dose of PT-141?

At 5 mg/mL, a 1.75 mg dose is 35 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 5 doses.

How strong is the evidence behind these PT-141 doses?

PT-141 is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published

Bremelanotide for hypoactive sexual desire disorder (RECONNECT) Kingsberg SA, et al. Obstetrics & Gynecology, 2019

The pivotal phase 3 trials establishing the 1.75 mg dose.

Find on PubMed ↗

Bremelanotide safety — blood pressure and nausea profile Clayton AH, et al. Journal of Sexual Medicine, 2019

The safety dataset behind the once-per-24-hour restriction.

Find on PubMed ↗

Newest Studies — —

—

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

PT-141 Dosage & Reconstitution